



**Table 1: Benefits, Limitations, and Risks of Available PrEP Regimens**

All PrEP Regimens	Oral PrEP With TDF/FTC or TAF/FTC	Injectable PrEP With CAB LA	Injectable PrEP With SC LEN
<i>Benefits</i>			
<ul style="list-style-type: none"> <li>Highly effective when taken as directed</li> <li>May decrease anxiety regarding HIV acquisition</li> <li>Engages sexually active at-risk individuals in care who are then screened regularly for STIs</li> </ul>	<ul style="list-style-type: none"> <li>99% effective in reducing the risk of HIV acquisition when used as prescribed</li> <li>TDF/FTC: Indicated for all sexual and injection exposures</li> <li>TAF/FTC: Indicated for sexual exposures in MSM and in transgender women who have sex with men</li> <li>Single tablet taken daily, or for TDF/FTC can also be taken before and after sex</li> <li>Good safety profiles in people who do not have HIV</li> <li>Minimal adverse effects, most of which resolve quickly or can be managed</li> <li>TDF/FTC appears to be safe for use during attempts to conceive and during pregnancy</li> <li>Treats HBV infection</li> </ul>	<ul style="list-style-type: none"> <li>Statistical superiority to TDF/FTC has been attributed to a lack of adherence to the oral regimen</li> <li>Indicated for all sexual exposures</li> <li>Administered intramuscularly once every 2 months</li> <li>Directly observed therapy</li> <li>Advantageous option when adherence to oral PrEP may be challenged by ongoing substance use or mental health concerns, neurocognitive disorders, difficulty swallowing pills, privacy concerns, or other challenges</li> </ul>	<ul style="list-style-type: none"> <li>Statistical superiority to TDF/FTC has been attributed to a lack of adherence to the oral regimen</li> <li>Indicated for all sexual exposures</li> <li>Administered subcutaneously once every 6 months</li> <li>Directly observed therapy</li> <li>Advantageous option when adherence to oral PrEP may be challenged by ongoing substance use or mental health concerns, neurocognitive disorders, difficulty swallowing pills, privacy concerns, or other challenges</li> </ul>
<i>Limitations</i>			
<ul style="list-style-type: none"> <li>Protection correlates with adherence to the dosing schedule</li> <li>No significant protection against STIs other than HIV (some protection against HSV reported in heterosexual populations without HIV)</li> </ul>	<ul style="list-style-type: none"> <li>Requires adherence to the daily administration schedule</li> <li>No data on TAF/FTC for individuals who inject drugs</li> <li>Requires planning and adherence when TDF/FTC is dosed on demand</li> <li>Requires additional monitoring in individuals with chronic HBV infection</li> <li>Cost of TAF/FTC (no generic available)</li> </ul>	<ul style="list-style-type: none"> <li>Requires deep IM injection</li> <li>No data for individuals who inject drugs</li> <li>Requires oral medications as bridging therapy when injections are missed</li> <li>Requires ≥6 in-person healthcare visits per year</li> <li>Does not treat HBV infection</li> <li>Not appropriate for individuals with injectable silicone or other fillers in the gluteal area</li> <li>Implementation logistics</li> <li>Cost (no generic available)</li> </ul>	<ul style="list-style-type: none"> <li>Increased risk of long-term impactful medication interactions</li> <li>Data pending for individuals who inject drugs</li> <li>Requires oral medications as bridging therapy when injections are missed</li> <li>Does not treat HBV infection</li> <li>Implementation logistics</li> <li>Cost (no generic available)</li> </ul>
<i>Risks</i>			
<ul style="list-style-type: none"> <li>Potential for delayed detection of HIV infection using standard HIV testing algorithms</li> <li>Continued use after undiagnosed HIV infection may result in development of drug-resistant virus</li> </ul>	<ul style="list-style-type: none"> <li>Safety concerns for individuals with impaired kidney function</li> <li>Compared with TAF, TDF may be associated with reversible decreases in bone density</li> </ul>	<ul style="list-style-type: none"> <li>Potential ISRs and other adverse events, including pyrexia</li> <li>Long tail phase once treatment is discontinued</li> <li>Potential for breakthrough infections despite on-time injections</li> </ul>	<ul style="list-style-type: none"> <li>ISRs are common (nodules, pain, and erythema at injection site)</li> <li>Long tail phase once treatment is discontinued</li> <li>Potential for breakthrough infections despite on-time injections</li> </ul>